Registration - In-house Corporation

Merck Canada Inc. / David D. Jones, PRESIDENT

Registration Information

In-house Corporation name: Merck Canada Inc.
Previous in-house corporation names
Responsible Officer Name: David D. Jones, PRESIDENT
Responsible Officer Change History
Initial registration start date: 2001-02-01
Registration status: Active
Registration Number: 959141-12241

Associated Communications

Total Number of Communication Reports: 199

Monthly communication reports in the last 6 months: 1

Version 33 of 45 (2017-08-16 to 2017-09-20)

Registration versions:

Version 33 of 45 (2017-08-16 to 2017-09-20)

Lobbying Information

Subject Matters

Aboriginal Affairs
Agriculture
Constitutional Issues
Consumer Issues
Defence
Economic Development
Education
Employment and Training
Energy
Environment
Financial Institutions
Government Procurement
Health
Immigration
Industry
Infrastructure
Intellectual Property
Internal Trade
International Relations
International Trade
Justice and Law Enforcement
Labour
Regional Development
Research and Development
Science and Technology
Small Business
Sports
Taxation and Finance
Telecommunications
Tourism
Transportation

Subject Matter Details

Legislative Proposal, Bill or Resolution

Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry. Budget 2015, 2016, and related updates as they relate to the biopharmaceutical industry, and to Federal budgetary policy.
Income Tax Act as it relates to biopharmaceutical products.
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.

Legislative Proposal, Bill or Resolution, Regulation

Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.

Policies or Program

Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs.
Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant.
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services.
Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization.
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits.
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations.
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG).

Regulation

Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
New Substances Notification Regulations as it relates to the biopharmaceutical industry.
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products.
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
Smart Regulations as it relates to the biopharmaceutical industry.

Communication Techniques

Written communication
Oral communication

Government Institutions

Agriculture and Agri-Food Canada (AAFC)
Canadian Institutes of Health Research (CIHR)
Canadian International Trade Tribunal (CITT)
Competition Tribunal (CT)
Employment and Social Development Canada (ESDC)
Environment and Climate Change Canada (ECCC)
Finance Canada (FIN)
Fisheries and Oceans Canada (DFO)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Indigenous and Northern Affairs Canada
Innovation, Science and Economic Development Canada (ISED)
Justice Canada (JC)
National Research Council (NRC)
Natural Resources Canada (NRCan)
Natural Sciences and Engineering Research Council (NSERC)
Office of the Information Commissioner of Canada (OIC)
Office of the Privacy Commissioner of Canada (OPC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Safety Canada (PS)
Public Services and Procurement Canada (PSPC)
Senate of Canada
Statistics Canada (StatCan)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

In-house Corporation Details

Description of activities

For 125 years, Merck has been working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines and animal health products. In Canada, Merck markets more than 250 pharmaceutical and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines and women's health, and is focused on expanding offerings in other areas, including virology, oncology and diabetes. Based in Montréal, Québec, Merck employs approximately 795 people across Canada. Merck is one of the top R&D investors in Canada, with investments totalling $29.9 million in 2014 and more than $1 billion since 2000. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube.

Responsible officer name and position during the period of this registration

Chirfi Guindo, PRESIDENT

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
16750 TransCanada Highway
Kirkland, QC H9H 4M7
Canada

Telephone number: 514-428-7920
Fax number: 514-428-4955

Parent Company Information

MERCK FROSST COMPANY
- 1959 Upper Water Street
  Suite 900
  Halifax, NS B3J 2X2
  Canada

Subsidiary Beneficiary Information

Merck Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Jennifer Chan, Vice President, Policy & Communications | No public offices held
Tama Donoahue-Walker, Vice President, Patient Access | No public offices held
Chirfi Guindo, President | No public offices held
Jeffrey Malawski, National Manager, Public Health | No public offices held
Sandra Wainwright, Director - Regulatory Affairs | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Kathy Armstrong, Manager, Patient Access - Ontario | No public offices held
Chad Jarema, Dir, Market Access, Strat Pricing Contracting & Negotiation | No public offices held
Robert Livingston, Director, Federal Government Affairs | No public offices held
Wendy Morton, Manager, National Policy | No public offices held

Merck Canada Inc.

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Merck Canada Inc.	2011-01-01	current
MERCK FROSST CANADA LTD.	2008-07-08	2011-01-01

The following names have been used before July 2, 2008

MERCK FROSST CANADA LTD.
MERCK FROSST CANADA INC

Merck Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
David D. Jones	2024-09-01	Current
Marwan Akar	2021-09-17	2024-09-01
Anna Van Acker	2017-12-14	2021-09-17
Chirfi Guindo	2014-10-01	2017-12-14
Thomas Cannell	2013-01-01	2014-10-01
Cyril Schiever	2011-07-01	2013-01-01
Carlos Dourado	2009-11-02	2011-07-01
DAWN GRAHAM	2001-02-01	2009-11-02

Date Modified:: 2025-03-12

Search and menus

Language selection

Registration - In-house Corporation

Merck Canada Inc. / David D. Jones, PRESIDENT

Registration Information

Associated Communications

Version 33 of 45 (2017-08-16 to 2017-09-20)

Version 33 of 45 (2017-08-16 to 2017-09-20)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties